Contribution: Industrial Research Assistance Program – Contributions to Firms
Providence Therapeutics Holdings Inc.
$10,000,000.00
Providence COVID-19 Vaccine Development - STAGE 3
EF 2022-23 · 2022-09-01
Résumé
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Calgary|Calgary, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
738045079
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2023-03-15
Agreement Number
998413
Agreement Start Date
2022-09-01
Agreement Title
Providence COVID-19 Vaccine Development - STAGE 3
Agreement Title (French)
Développement du vaccin Providence COVID-19 - STADE 3
Agreement Type
Contribution
Agreement Value
$10,000,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
Description (French)
Providence Therapeutics a l’intention de poursuivre le développement clinique d’un vaccin à ARNm fabriqué au Canada contre la COVID-19. L’entreprise prévoit de lancer un essai clinique de phase 3 sur le PTX-COVID19-B à la mi-2023 et de demander des autorisations de mise sur le marché ou d’urgence pour commercialiser le vaccin à la fin de 2023 ou au début de 2024. L’objectif de ce projet est de faciliter les efforts de R-D de l’entreprise et le programme de développement du vaccin afin de commencer un essai clinique de phase 3 en 2023.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Calgary Shepard
Federal Riding (French)
Calgary Shepard
Federal Riding Number
48011
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
738045079
Recipient City
Calgary|Calgary
Recipient Country
CA
Recipient Legal Name
Providence Therapeutics Holdings Inc.
Recipient Postal Code
T2Z 3P2
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2022-2023-Q3-998413
